27 marzo 2018 anni - FDA held a meeting of the Psychopharmacologic Drugs Advisory Committee to discuss the new drug application for lofexidine hydrochloride, submitted by US WorldMeds, LLC, for mitigation of symptoms associated with opioid withdrawal and facilitation of completion of opioid discontinuation treatment.

Aggiunto al nastro di tempo:

Opioids and the FDA

ByAnastasia

13 nov 2018

0 0 330

Data: